Patents by Inventor Jonathan Carlson

Jonathan Carlson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240143502
    Abstract: An apparatus and method for implementing a Level 0 cache within a cache subsystem. For example, one embodiment of a processor comprises: a cache subsystem comprising a Level-0 cache; a scheduler to schedule a load operation indicating data to be loaded; and a load hit predictor to predict whether the data indicated by the load operation is stored in the LO cache and to generate a wakeup signal to the scheduler in response to predicting that the data is stored in the LO cache. Some implementations perform store forwarding in response to load operations using a multi-step approach in which a partial linear address check is performed to determine load operations which are eligible for store forwarding. A full address check is performed for those load operations which are eligible in which the address of the load is compared against the address of a youngest older store operation.
    Type: Application
    Filed: October 1, 2022
    Publication date: May 2, 2024
    Inventors: Mark DECHENE, Thomas MULLINS, Ryan CARLSON, Paula PETRICA, Brendan WEST, Jonathan JOHNSON, Nikhil PATIL
  • Publication number: 20240058455
    Abstract: The present disclosure provides bioorthogonal linkers and reagents, including trans-cyclooctene (“TCO”)- and tetrazine (“Tz”)-containing compounds. In a general aspect, the present disclosure provides reagents, conjugates, and bioactive molecules containing a trans-cyclooctene (“TCO”) fragment. Examples of TCO fragments include: Formulae (I) and (II).
    Type: Application
    Filed: October 4, 2021
    Publication date: February 22, 2024
    Inventors: Jonathan Carlson, Hannes Mikula, Ralph Weissleder
  • Publication number: 20200188535
    Abstract: This present application relates to fluorescent tetrazine-containing compounds consisting of a single pi-system. For example, a compound of Formula (I): F-L-Tz or a salt thereof, wherein: F is a fluorophore, L is a conjugated linker, and Tz is a substituted or unsubstituted tetrazine; wherein the linker bridges the Tz and F moieties in a single conjugated pi-system. Also provided herein are methods of using the compounds provided herein for biomedical imaging.
    Type: Application
    Filed: December 16, 2019
    Publication date: June 18, 2020
    Inventors: Labros Meimetis, Jonathan Carlson, Ralph Weissleder
  • Patent number: 10517965
    Abstract: This present application relates to fluorescent tetrazine-containing compounds consisting of a single pi-system. For example, a compound of Formula (I): or a salt thereof, wherein: F is a fluorophore, L is a conjugated linker, and Tz is a substituted or unsubstituted tetrazine; wherein the linker bridges the Tz and F moieties in a single conjugated pi-system. Also provided herein are methods of using the compounds provided herein for biomedical imaging.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: December 31, 2019
    Assignee: The General Hospital Corporation
    Inventors: Labros Meimetis, Jonathan Carlson, Ralph Weissleder
  • Publication number: 20160121002
    Abstract: This present application relates to fluorescent tetrazine-containing compounds consisting of a single pi-system. For example, a compound of Formula (I): or a salt thereof, wherein: F is a fluorophore, L is a conjugated linker, and Tz is a substituted or unsubstituted tetrazine; wherein the linker bridges the Tz and F moieties in a single conjugated pi-system. Also provided herein are methods of using the compounds provided herein for biomedical imaging.
    Type: Application
    Filed: May 6, 2014
    Publication date: May 5, 2016
    Applicant: The General Hospital Corporation
    Inventors: Labros Meimetis, Jonathan Carlson, Ralph Weissleder
  • Patent number: 5585254
    Abstract: The present invention relates to novel recombinant autonomous parvovirus vectors, novel recombinant virus particles, and novel gene delivery vehicles that can be used to selectively target heterologous nucleic acid sequences to desired cell types and to selectively express such sequences in such desired cell types. Recombinant autonomous parvovirus gene delivery vehicles are particularly advantageous for transient gene therapy, and are especially well-suited to treat diseases in which there is rapid cell growth, such as cancer. Also included is the use of recombinant vectors of the present invention to produce RNA and protein products in cell culture.
    Type: Grant
    Filed: April 2, 1993
    Date of Patent: December 17, 1996
    Assignee: University of Colorado Foundation, Inc.
    Inventors: Ian H. Maxwell, Jonathan Carlson, Joseph A. Corsini, Fran.cedilla.oise Maxwell, Solon L. Rhode